Andrew N. Shen Ph.D.
Staff Fellow — Division of Neurotoxicology
Andrew N. Shen, Ph.D.
(870) 543-7121
NCTRResearch@fda.hhs.gov
Back to NCTR Principal Investigators page
Background
Dr. Shen received a bachelor’s degree in cognitive psychology from Marquette University in Milwaukee, WI. He received an M.S. and a Ph.D. in behavioral neuroscience from Auburn University in Auburn, AL. Prior to joining FDA, Dr. Shen was a postdoctoral scholar at the University of Kentucky's Sanders-Brown Center on Aging (2016-2018) and a postdoctoral fellow at FDA’s National Center for Toxicological Research (NCTR) through the Oak Ridge Institute for Science and Education (ORISE) (2019). Presently, he is a staff scientist in NCTR’s Division of Neurotoxicology.
Research Interests
Dr. Shen’s research focuses on characterizing the neurobehavioral and neurovascular consequences of drugs, heavy metals, and other compounds with potential neurotoxicity. In particular, his work aims to elucidate the connection between neurovascular dysfunction and changes in cognitive processes. His laboratory utilizes diverse methods to answer regulatory toxicology questions, which range from live-cell confocal microscopy and protein assays to neurobehavioral assays and complex cognitive tasks. Currently, Dr. Shen is collaborating with colleagues to assess potential developmental neurotoxicity of cannabidiol (CBD) as well as potential neuroimmune effects of developmental CBD exposure.
Professional Societies/National and International Groups
Society of Toxicology
Member
2013 – Present
Selected Publications
Neurobehavioral and Neurochemical Effects of Perinatal Arsenite Exposure in Sprague-Dawley Rats.
Flanigan, T.J., Ferguson, S.A., Law, C.D., Rosas-Hernandez, H., Cuevas-Martinez, E., Fitzpatrick, S., and Shen, A.N.
Neurotoxicology and Teratology. 2022, 90, 107059.
Methylmercury Exposure and its Implications for Aging.
Shen A.N. and Newland M.C.
Assessments, Treatments and Modeling in Aging and Neurological Disease. 2021, 213-224.
Isolation of Cerebral Capillaries from Fresh Human Brain Tissue.
Hartz A.M., Schulz J.A., Sokola B.S., Edelmann S.E., Shen A.N., Rempe R.G., Zhong Y., Sebloni N.E., and Bauer B.
Journal of Visualized Experiments: JoVE. 2018, (139).
Preventing P-gp Ubiquitination Lowers Aβ Brain Levels in an Alzheimer’s Disease Mouse Model.
Hartz A., Zhong Y., Shen A.N., Abner E.L., and Bauer B.
Frontiers in Aging Neuroscience. 2018, 10, 186.
Aging, Motor Function, and Sensitivity to Calcium Channel Blockers: An Investigation Using Chronic Methylmercury Exposure.
Shen A.N., Cummings C., Hoffman D., Pope D., Arnold M., and Newland M.C.
Behavioural Brain Research. 2016, 315, 103-114.
A Bout Analysis Reveals Age-Related Methylmercury Neurotoxicity and Nimodipine Neuroprotection.
Shen A.N., Cummings C., Pope D., Hoffman D., and Newland M.C.
Behavioural Brain Research. 2016, 311, 147-159.
Examination of Clozapine and Haloperidol in Improving Ketamine-Induced Deficits in an Incremental Repeated Acquisition Procedure in BALB/c Mice.
Shen A.N. and Newland M.C.
Psychopharmacology. 2016, 233(3), 485-498.
- Contact Information
- Andrew N. Shen
- (870) 543-7121
- Expertise
-
ExpertiseNeurotoxicology